Twitter Facebook LinkedIn

Leadership

Patricia Bradford, PhD
Microbiology Consultant
Antimicrobial Development Specialists, LLC

Patricia A. Bradford is the owner of Antimicrobial Development Specialists LLC, a consulting company that focuses on the late-stage development of antibiotics. Prior to this she was at AstraZeneca and was responsible for the microbiology support contributing to the successful development and approval of ceftazidime-avibactam. Before joining AstraZeneca, Dr. Bradford worked in antibiotic research for Novartis, Wyeth Pharmaceuticals and Lederle Laboratories. During her tenure at Wyeth she worked on a number of antibiotic projects and was instrumental in the team that wrote the dossier for the registration and approval of tigecycline. She was also heavily involved in the studies for several sNDA applications for piperacillin-tazobactam.

Dr. Bradford is fellow in the American Academy of Microbiology, has over 100 publications in peer-reviewed scientific journals and has written several review articles and book chapters. She served as an editor for Antimicrobial Agents Chemotherapy 2001-2011 and is currently a Senior Editor for ASM’s newest journal, mSphere. She is also an active participant with the subcommittee on Antimicrobial Susceptibility Testing of the Clinical Laboratory Standards Institute.

Prior to working industry, she worked as a clinical microbiologist at Nebraska Methodist Hospital in Omaha. Dr. Bradford received a B.S. in Medical Technology from the University of Nebraska Medical Center, Ph.D. in Medical Microbiology from Creighton University and completed a post-doctoral fellowship in β-lactamase research.